ClinicalTrials.gg
RecruitingNCT05690581Updated Dec 27, 2024

Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies

A Phase 1 interventional study of CM369 in Advanced Solid Tumors and Hematologic Malignancies, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
146
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Hematologic Neoplasms with a site in China — 76 open to participants now, 84 under way, 8 of them phase 3. Hematologic Neoplasms · China.

Planned enrollment
30th of 123
146 · median 56
Started
2023
with 19 others
Phase 1
57 of 149
30 open now
Primary completion
2025-10
later than 20 of 83 live
Registered
73rd of 149
by date

Among the 149 studies in Hematologic Neoplasms with a site in China, this one is the 30th largest by planned enrollment of the 123 interventional ones that give a count, is one of 20 that started in 2023, is one of 57 in phase 1, reaches primary completion later than 20 of the 83 other live ones, and was the 73rd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

76 of the 149 studies in Hematologic Neoplasms with a site in China are open now. Recruiting first, the newest first:

71 more — sign in →

All 76 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Hematologic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a nonrandomized, open-label, multicenter, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of CM369 in subjects with advanced solid tumors and Hematologic Malignancies.

03

Conditions studied

  • Advanced Solid Tumors and Hematologic Malignancies
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Solid tumor Inclusion Criteria:

  1. ≥12 weeks.
  2. performance status of 0-1.
  3. Subjects with cytology and/or confirmed locally advanced unresectable or solid tumors.
  4. Agree to provide archived tumor tissue samples of primary or metastatic lesions.
  5. Phase Ia: have at least one or one evaluable lesion according to 1.1.
  6. Have adequate organ function as described in the protocol.

Hematologic Inclusion Criteria:

  1. Male and female subjects ≥18 years of age and ≤ 75 years of age.
  2. This study enroll subjects with recurrent/ hematological tumors.
  3. The subjects must have measurable lesions.
  4. Positive CCR8in tumor tissues of subjects.
  5. Eastern Cooperative Oncology Group performance status (ECOG) of ≤2, and had a Life expectancy of at least 3 months.
  6. Adequate hematological function, defined as protocol.
  7. Subjects with normal coagulation function, defined as protocol.
  8. Adequate hepatic, renal and cardiac functions, defined as protocol.
  9. Subjects voluntarily signed form (ICF) and written informed consent must be obtained prior to performing any study-related procedure.
  10. Women of (WOCBP) must have a negative serum pregnancy test within 7 days prior to receiving the first dose of study medication.
  11. WOCBP or male subjects and their female partners of childbearing potential must be willing to use an appropriate method of during the study and for 6 months after the last dose, and must not donate eggs or sperms during this period.
  12. Female subjects were not allowed to breastfeed during the study and for at least 6 months after the last dose of study medication.

Exclusion criteria

Exclusion Criteria:

Solid tumor Exclusion Criteria:

  1. Subjects with primary central nervous system (CNS) tumors or unstable .
  2. Subjects who have uncontrollable or major cardiovascular disease refer to protocol.
  3. Subjects who have an active disease or have had an autoimmune disease with risk of recurrence.
  4. Subjects who have active or history of interstitial lung disease or non-infectious pneumonia.
  5. Subjects with any active infection requiring systemic treatment by intravenous infusion within 14 days prior to the first administration of the study drug.
  6. infection; virus (HCV) antibody positive; HCV infection.
  7. History of active bleeding within 2 months before screening, or bleeding symptoms associated with application of anticoagulant drugs or other interventions.
  8. Have not recovered to Grade 1 or better from the adverse events due to previous cancer therapies.
  9. Subjects who received systemic drugs within 14 days prior to the first administration of the study drug.
  10. Subjects who require systemic treatment of or other immunosuppressive agents within 14 days prior to first dose.
  11. Has a history of severe allergic reactions to monoclonal antibodies.
  12. Subjects with any mental or cognitive impairment that may limit their understanding, implementation.

Hematologic Exclusion Criteria:

  1. Previous treatment with
  2. hematopoietic stem cell transplantation within 100 days prior to first medications dose, or history of allogeneic hematopoietic stem cell transplantation.
  3. Subjects currently suffering from acute (GVHD) or active chronic GVHD.
  4. Have had any therapy directed against the subject's underlying cancer within 28 days prior to first investigational medications dose.
  5. Received other clinical trial drugs within 28 days prior to first investigational medications dose.
  6. Subjects who experienced major organ surgery (except for needle ) or significant trauma within 28 days prior to first investigational medications administration, or who need selected surgical procedures during the study.
  7. Subjects who have been vaccinated with within 28 days prior to first investigational medications administration.
  8. Clinical evidence of central nervous system (CNS) will be excluded.
  9. Previous or concomitant with CNS diseases.
  10. History of another primary malignancy not in remission for at least 2 years.
  11. Any severe active infection requiring systemic antimicrobial therapy.
  12. Active or C virus infection.
  13. History of immunodeficiency, including human immunodeficiency virus (HIV) antibody positive or known syphilis infection.
  14. History of severe cardiovascular and cerebrovascular diseases.
  15. Subjects who currently or have suffered from severe interstitial lung disease.
  16. The toxicity of previous anti-tumor therapy is still ≥ grade 2 at enrollment.
  17. History of severe bleeding disorders,.
  18. Known alcohol or drug dependence.
  19. Subjects with mental disorders or poor compliance.
  20. Pregnant or lactating female subjects.
  21. Any other condition that, in the opinion of the investigator or project clinician, would interfere with a subject's ability to receive or complete the study.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
146 participants (estimated)

Study arms

  • Experimental
    CM369 Ia Dose Escalation

    Dose escalation of CM369 as monotherapy

    Drug: CM369

  • Experimental
    CM369 Ib Dose Expansion

    Dose expansion of CM369 as monotherapy

    Drug: CM369

Interventions

  • DrugCM369

    Specified dose on specified days.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Time frame: 90 weeks

  2. Serious Adverse events (SAEs)

    Time frame: 90 weeks

  3. Dose limiting toxicities (DLTs)

    Time frame: 90 weeks

Secondary outcomes

  1. PK parameter: Peak Time (Tmax)

    Time frame: 90 weeks

  2. PK parameter: Half-life (t1/2)

    Time frame: 90 weeks

  3. PK parameter: Area Under the Curve (AUC)

    Time frame: 90 weeks

  4. PK parameters: Clearance (CL)

    Time frame: 90 weeks

  5. PK parameter: Apparent volume of distribution of steady state (Vss)

    Time frame: 90 weeks

  6. Immunogenicity: Incidence of anti-CM369 antibody

    Time frame: 90 weeks

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Oct 2025, 32 months after the start.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 32 months is below that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Jan 19, 2023
StartActual
Feb 23, 2023
Primary completionEst.
Oct 30, 2025
CompletionEst.
Feb 28, 2026
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05690581
Responsible party
Sponsor
First posted
Jan 19, 2023
Start date
Feb 23, 2023
Primary completion
Oct 30, 2025 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Dec 27, 2024

Study contacts

Ruihua Xu
Contact
xurh@sysucc.org.cn
13922296676

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion